Medivir (0GP7.L) Stock Analysis & AI Equity Report
Medivir (0GP7.L) overview
Medivir (0GP7.L) stock analysis and AI equity research. For the latest completed financial year, 2022, Medivir reported revenue of SEK 4.4m and operating profit of SEK -87.4m; the year-end share price was N/A and market capitalisation was N/A. Medivir is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Medivir's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-29. Data will be refreshed during report generation.
About Medivir
Medivir is a pharmaceutical company focused on developing and commercializing innovative treatments in areas of high unmet medical need, with a current pipeline led by fostrox for liver cancer and other clinical and partnered projects. It also has an outlicensed product, Xerclear/Zoviduo, for labial herpes.
Generate the Medivir report
Medivir is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Medivir and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.